Cellectis announced it is exiting CAR-T programs and shifting toward “in vivo” gene editing, citing changes in the cell-therapy landscape and the need to reallocate resources. The move underscores how donor-derived CAR-T strategies have become increasingly challenged by competitive alternatives and evolving platform economics. At the same time, Cellectis has also been preparing to align around long-lasting treatment concepts for chronic disease, consistent with its broader platform narrative. The shift suggests the company will concentrate development efforts where its gene-editing platform can deliver durability without relying on ex vivo manufacturing. For the sector, the pivot adds to an ongoing reshuffle in cell therapy, where companies are reassessing pipeline architecture and manufacturing burden against clinical differentiation potential.